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PCardiovascular Effects of Stress
nhibition of Cortisol Production With
etyrapone Prevents Mental Stress-Induced
ndothelial Dysfunction and Baroreflex Impairment
ndrew J. M. Broadley, MRCP,* Ania Korszun, MRCPSYCH,† Eltigani Abdelaal, MRCP,‡
alentina Moskvina, PHD, Christopher J. H. Jones, FRCP,¶ Gerard B. Nash, PHD,§ Clare Ray, PHD,§
ohn Deanfield, FRCP,# Michael P. Frenneaux, FRCP, FACC‡
orquay, London, Birmingham, and Wales, United Kingdom
OBJECTIVES This study was designed to investigate the role of cortisol in stress-induced endothelial
dysfunction and impaired baroreflex sensitivity (BRS) by blocking cortisol production with
metyrapone before subjecting healthy volunteers to mental stress.
BACKGROUND Mental stress raises cortisol levels and is associated with increased coronary heart disease
(CHD) morbidity and mortality, especially from sudden cardiac death. It also causes
endothelial dysfunction and impaired BRS.
METHODS We measured brachial artery flow-mediated dilation (FMD), a measure of endothelial
function, and BRS in 36 subjects without CHD risk factors who were then randomized in a
double-blind fashion to oral metyrapone 750 mg 2 or placebo. Five hours later we subjected
subjects to mental stress and then remeasured endothelial function and BRS.
RESULTS Prestress cortisol levels were significantly higher in the placebo group at 270.5 (30.9) nmol/l
versus 89.1 (11.8) nmol/l (p  0.01), and the increase with stress was higher at 57.9 (17.9)
nmol/l versus 11.2 (2.2) nmol/l (p  0.001). In the placebo group, compared to baseline,
FMD and BRS fell significantly from 4.5% (0.7%) to 1.4% (1.1%) (p  0.02) and 21.4 (2.3)
ms/mm Hg to 16.3 (1.5) ms/mm Hg (p  0.04), respectively. In the metyrapone group,
FMD and BRS were unchanged from baseline: 4.3% (0.9%) versus 5.1% (0.8%) (p  0.48)
and 26.4 (2.9) ms/mm Hg versus 24.9 (2.6) ms/mm Hg (p  0.62), respectively. Analysis of
covariation showed a significant effect of metyrapone on change in both FMD (p  0.009)
and BRS (p  0.024).
CONCLUSIONS Stress-related endothelial dysfunction and BRS impairment can be prevented by blocking
cortisol production with metyrapone, demonstrating a direct or facilitative role for cortisol in
these phenomena and suggesting mechanisms by which stress contributes to CHD and
sudden cardiac death. (J Am Coll Cardiol 2005;46:344–50) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.068College of Cardiology Foundation
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ahere is a clustering of nonfatal and fatal cardiac events
ollowing stressful life events (1). Acute mental stress has
een shown to trigger myocardial ischemia (2), induce
ransient (90 min) endothelial dysfunction in healthy
oung subjects (3), and impair baroreflex sensitivity (BRS)
4,5). Cortisol is a key component of the stress response,
nd short-term high-dose oral cortisol administration has
reviously been shown to impair endothelial function in
ealthy subjects (6). We hypothesized that cortisol mediates
he impairment of both endothelial function and BRS by
cute mental stress and tested this by inhibiting cortisol
ynthesis with metyrapone, a competitive inhibitor of the
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005, accepted March 29, 2005.onversion of 11-deoxycortisol to cortisol by adrenal 11-
eta-hydroxylase.
ETHODS
ubjects. We conducted a randomized, double-blind
lacebo-controlled trial. Ethical permission was obtained
rom our local research ethics committee. Thirty-six healthy
onsmoking subjects gave informed consent and partici-
ated. Exclusion criteria included a history of heart disease
r any traditional risk factor for coronary heart disease
CHD) (smoking within the past 10 years, hypertension,
iabetes, or hypercholesterolemia). Other exclusion criteria
ere a body mass index 30; current pregnancy or meno-
ause; or any other condition, drug treatment, or dietary
upplements known or likely to affect the measured vari-
bles. Subjects were ages 18 to 55 years.
aroreflex sensitivity. Subjects were initially studied in the
orning beginning at 8:30 AM, fasting and having avoided
lcohol for at least 24 h and caffeine for at least 12 h. On
rrival their height and weight were measured, their cardio-
ascular systems were examined, and a 12-lead electrocar-
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July 19, 2005:344–50 Stress and Endothelial Dysfunctioniogram (ECG) was performed. After attachment to an
CG monitor and fitting of a Portapres noninvasive con-
inuous blood pressure monitor (TNO Biomedical Instru-
entation, Affligem, Belgium), subjects rested supine in a
uiet, temperature-controlled environment for 20 min. For
he next 10 min heart rate and blood pressure were recorded.
nalog output from the ECG monitor and the Portapres
ere fed into an analog-to-digital converter (Biopac, Biopac
ystems Inc., Goleta, California), and output from the
onverter was fed into a personal computer and recorded at
00 Hz using AcqKnowledge software (Biopac Systems
nc.) for later calculation of BRS by the “spontaneous
equence” method (7–9). Briefly, each systolic blood pres-
ure measurement was matched with the following RR
nterval. A proprietary program was then used to seek
sequences” in which both systolic pressure and RR interval
ncreased or decreased together for three or more beats.
inimum increments were 1 mm Hg and 2 ms. A second
rogram selected those sequences in which systolic blood
ressure and RR interval had a correlation coefficient of 0.85
r higher. The mean gradient of these sequences, expressed
n ms/mm Hg, was taken as BRS.
ndothelial function. Flow-mediated dilation (FMD) of
he brachial artery was then measured using a technique
reviously validated in our department (10). Briefly, high-
esolution ultrasound (7.5 MHz) was used to visualize the
rachial artery above its bifurcation at the elbow. An
-mode of the ultrasound image was fed to a wall tracking
ystem (Vadirec 101, Medical Systems Arnhem, Ooster-
rek, the Netherlands), which is able to determine the
iastolic diameter of the artery to within 10 m. A wrist cuff
as inflated to and maintained at between 250 and 300 mm
g for 5 min and then released, causing reactive hand
yperaemia, which in turn led to increased flow through the
bserved segment of brachial artery. Increased flow through
n artery increases the shear stress at the blood-endothelium
nterface and stimulates healthy endothelial cells to produce
he vasodilator nitric oxide (NO). Some of the NO pro-
uced diffuses into the vascular smooth-muscle layer adja-
ent to the endothelium, inducing relaxation and vessel
ilation. The dilation of the brachial artery in response to
ncreased flow (the FMD) was measured at 1-min intervals
Abbreviations and Acronyms
BRS  baroreflex sensitivity
CHD  coronary heart disease
ECG  electrocardiogram
ET  endothelin
FMD  flow-mediated dilation
GTN  glyceryl trinitrate
GTNMD  glyceryl trinitrate-mediated endothelium-
independent dilation
HUVEC  human umbilical vein endothelial cell
NO  nitric oxide
NOS  nitric oxide synthaseor the next 8 min. The greatest change from baseline fithin the first 3 min was taken to be FMD and was
xpressed as percent of baseline diameter. Once the artery
ad returned to baseline diameter, 1 ml of glyceryl trinitrate
GTN) solution containing 50 g of GTN was adminis-
ered sublingually, and brachial artery dilation was measured
min later as a measure of glyceryl trinitrate-mediated
ndothelium-independent dilation (GTNMD). In our lab-
ratory the coefficient of variation for repeated measures of
MD is 7%.
lood sampling. With the subjects still supine, blood was
aken for urea and electrolytes, full blood count, glucose,
riglycerides, cholesterol (total, high-density, and low-
ensity) and cortisol, all of which were analyzed in our
ospital’s main laboratory. Further samples were immedi-
tely placed in a centrifuge that had been prechilled to 4°C
nd spun at 3,000 rpm for 10 min. Plasma was then pipetted
ff and stored at 70°C for later measurement of cat-
cholamines. After venesection, the subjects were allowed to
it up and were given a standard low-fat snack and some-
hing to drink.
lacebo/metyrapone. Before their visit, subjects were ran-
omized to one of two groups: the metyrapone group was
iven metyrapone 750 mg with their snack and a further 750
g dose to be taken with their midday meal 3.5 h later. The
ontrol group was given placebos. We chose this dosing
chedule because earlier work has shown that this regime
roduces a significant reduction in plasma cortisol levels at
h and is well tolerated (11). Subjects were then allowed to
eave the laboratory and were asked to return 5 h later. They
ere asked to avoid heavy physical work or exercise in the
nterval between their visits. They were also asked to
ontinue abstaining from alcohol and caffeinated drinks and
o avoid fatty foods.
eturn visit. Subjects returned 5 h after taking the first
ose of metyrapone or placebo. They lay down and were
onnected to the ECG and Portapres as before. A 23-G
annula was sited in the right antecubital fossa for later
lood sampling and flushed with saline. After 20 min of
upine rest, as before, blood samples were taken from the
annula for catecholamine and cortisol levels. Subjects were
hen asked if they would be willing to undertake a simulated
ublic speaking task designed to place them under a degree
f mental stress before repeating the morning’s measure-
ents. All subjects agreed and were then played taped
nstructions asking them to imagine that they had been
alsely accused of a crime and were defending themselves to
he police. These instructions took 3 min and were followed
y 2 min of “thinking time” and 3 min of talking. We chose
his test because it has previously been shown to produce
ndothelial dysfunction in the brachial artery (12).
Blood pressure and heart rate were recorded continuously
y ECG and Portapres throughout the stress test and for 10
in afterwards, and poststress BRS was calculated from the
nal 10 min of this recording. Once this recording was
omplete, blood samples were again taken from the cannula
or cortisol and catecholamines. Finally, FMD of the
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Stress and Endothelial Dysfunction July 19, 2005:344–50rachial artery was measured again. On completion of the
econd FMD study, subjects graded the intensity of mental
tress induced by the test on a 10-point scale ranging from
no stress at all” to “very severe mental stress.”
n vitro studies. Metyrapone has been reported to have
enerally, but not exclusively, inhibitory effects on several
-450 enzyme systems, and endothelial nitric oxide syn-
hase (eNOS) is a P-450 enzyme. In order to exclude a
irect effect of metyrapone of NO production independent
f any effect of cortisol lowering, we undertook an in vitro
tudy with cultured human umbilical vein endothelial cells
HUVECs). Human umbilical vein endothelial cells were
solated from umbilical cords as previously described (13)
nd cultured in medium 199 (Gibco Invitrogen Com-
ounds, Paisley, United Kingdom), supplemented with 20%
etal calf serum, 10 ng/ml epithelial growth factor, 35 g/ml
entamycin, 1 g/ml hydrocortisone (all from Sigma-
ldrich, Poole, United Kingdom) and 2.5 g/ml ampho-
ericin B (Gibco Invitrogen Compounds). Confluent pri-
ary HUVECs were dissociated using trypsin/EDTA
Sigma), seeded into six-well culture plates (Falcon; Becton
ickinson Labware, New Jersey) and grown until confluent
3 days). The release of NO in response to 100 M
cetylcholine (ACh) was measured using an NO-sensitive
lectrode with a 2-mm diameter tip (ISO-NOP, WPI,
lorida) connected to a NO meter (ISO-NO Mark II,
PI, Berlin, Germany). The device was calibrated on each
xperimental day by chemical generation of NO (14) and
he response to ACh was expressed as the change in NO
utput from the baseline level 1 min before to the level
eached in the 10th minute after ACh administration.
uman umbilical vein endothelial cells were tested before
nd 180 min after the administration of metyrapone (5
g/ml) and at the same times in parallel untreated control
atients and in cultures treated with the vehicle for metyr-
pone (0.5% methanol).
tatistics. Group results are expressed as mean  SEM.
epeated measures within individuals were examined by
tudent paired t test; comparison of means between groups
as by Student nonpaired t test. Repeated measures analysis
f variation adjusted for baseline values was used to examine
he effect of metyrapone upon changes in measured param-
ters. A p value of 0.05 was considered significant.
ESULTS
aseline. Baseline demographic, hemodynamic, and he-
atologic characteristics did not differ significantly between
lacebo (n  17) and metyrapone groups, although systolic
lood pressure was nonsignificantly higher in the placebo
roup at baseline (Table 1). There was no difference between
lacebo and metyrapone groups for FMD, GTNMD, or
RS.
ffect of metyrapone. CORTISOL. Afternoon prestress
ortisol was significantly higher in the placebo group than in
he metyrapone group (270.5 [30.9] nmol/l vs. 89.1 [11.8] bmol/l, p  0.01). As expected, the increment in cortisol
esponse with stress was significantly greater in the placebo
roup (57.9 [17.9] nmol/l vs. 11.2 [2.2] nmol/l, p  0.001).
LOOD PRESSURE AND HEART RATE RESPONSE TO STRESS.
fternoon prestress systolic and diastolic blood pressure and
eart rate did not differ significantly between groups. The
lood pressure response to stress was slightly (but not
ignificantly) blunted in the metyrapone group, but at no
oint was the difference in systolic or diastolic blood
ressure between the groups significant (Fig. 1A). Within
inutes of the end of the stress test, blood pressure had
tabilized in both groups and remained stable until the end
f the 10-min BRS recording, albeit at a slightly higher level
han before the test (Fig. 1A). In the placebo group,
oststress systolic and diastolic blood pressures were slightly
ut significantly higher than prestress values (systolic: 121
4.6] mm Hg vs. 127 [3.7] mm Hg, p 0.001; diastolic: 58
2.2] mm Hg vs. 61 [2.2] mm Hg, p  0.001). In the
etyrapone group there was no significant difference be-
ween pre- and poststress blood pressure values. Heart rate
rended to be lower prestress in the metyrapone group, and
he stress heart rate (at 6 min) was significantly lower in the
etyrapone group (76 [3.2] beats/min vs. 89 [4.3] beats/
in, p  0.03) (Fig. 1B). Poststress heart rates also trended
o be lower in the metyrapone group, but this difference was
ot significant.
MD AND GTNMD. Brachial artery diameter did not differ
ollowing mental stress in the metyrapone versus placebo
roups (3.03 [0.13] mm vs. 2.99 [0.13] mm, respectively, p
NS). Poststress FMD was lower than baseline FMD in
he placebo group (p 0.019) but was similar to baseline in
he metyrapone group (p  0.49). Analysis of variation
sing baseline FMD as covariate showed a significant effect
f metyrapone on poststress FMD (p  0.009). In contrast,
TNMD was not significantly different following stress
ompared with baseline in either group.
RS. As shown in Table 2, poststress BRS was lower than
able 1. Baseline Group Characteristics
Measurement (Unit) Metyrapone Placebo p Value
ge (yrs) 38.4 (2.7) 40.8 (2.1) NS
ody mass index (kg/m2) 24.1 (0.5) 24.8 (1.0) NS
ystolic BP (mm Hg) 108.6 (3.1) 117.2 (3.1) 0.06
iastolic BP (mm Hg) 68.6 (2.1) 71.5 (1.8) NS
eart rate (beats/min) 57.3 (2.2) 60.9 (2.2) NS
otal cholesterol (mmol/l) 4.4 (0.19) 4.7 (0.26) NS
asting triglycerides (mmol/l) 0.9 (0.11) 1.1 (0.12) NS
asting glucose (mmol/l) 4.9 (0.15) 4.8 (0.1) NS
lasma cortisol (nmol/l) 370 (33.5) 372 (29.4) NS
RS (ms/mm Hg) 26.4 (2.9) 21.4 (2.3) 0.19
rachial artery diameter (mm) 2.97 (0.13) 3.01 (0.13) NS
MD (%) 4.3 (0.93) 4.5 (0.71) NS
TNMD (%) 12.9 (2.1) 10.7 (1.2) NS
S  p  0.2.
BP  blood pressure; BRS  baroreflex sensitivity; FMD  flow-mediated
ilation; GTNMD glyceryl trinitrate-mediated endothelium-independent dilation.aseline BRS in the placebo group (p  0.042) but not in
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July 19, 2005:344–50 Stress and Endothelial Dysfunctionhe metyrapone group (p  0.620). Analysis of variance
sing baseline BRS as covariate showed a significant effect
f metyrapone on poststress BRS (p  0.024).
ubjective stress. There was no difference in subjective
ssessment of stress between groups (placebo 4.9 of 10 vs.
.6 of 10, p  0.56).
Figure 1. Hemodynamic response to mental stress. (a) Blood pressure r
able 2. Effect of Metyrapone on FMD, GTNMD, and BRS
Baseline vs. Post-Stress Stud
Placebo
MD (%) 4.5 [0.71] vs. 1.4 [1.11]
p  0.019
TNMD (%) 10.7 [1.33] vs. 10.1 [1.73]
p  0.89
RS (ms/mm Hg) 21.4 [2.25] vs.16.3 [1.48]
p  0.042NCOVA  analysis of covariation; other abbreviations as in Table 1.ther effects. There was no difference in the catechol-
mine response to stress between groups (data not shown).
efore beginning the study, subjects were asked to report
ny side effects after taking each tablet. Four subjects
eported minor lightheadedness of short duration about 20
in after taking the first tablets. Of these, two had taken
se to stress. (b) Heart rate response to stress. bpm  beats per minute.
Paired t Test
Effect of Metyrapone ANCOVA
(Covariate: Baseline)Metyrapone
3 [0.93] vs. 5.1 [0.79]
p  0.49
p  0.009
9 [2.14] vs. 11.6 [1.77]
p  0.35
p  0.990
4 [2.91] vs. 24.9 [2.60]
p  0.620
p  0.024ent’s
4.
12.
26.
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Stress and Endothelial Dysfunction July 19, 2005:344–50lacebo. One subject, who had taken metyrapone, reported
imilar lightheadedness after both doses of tablets. There
ere no other reported effects.
n vitro studies. Metyrapone did not alter nitric oxide
elease from cultured endothelial cells. Acetylcholine-
voked release of NO from HUVECs (45.7 [7.1] nM) was
ot significantly changed 180 min after metyrapone admin-
stration (42.4 [7.3] nM; mean  SEM from 6 paired
xperiments). In addition, in matched untreated time con-
rols, the NO response to ACh (38.9 [2.2] nM) was
nchanged after 180 min (41.2 [1.8] nM; n  6). Finally,
he vehicle for metyrapone, 0.5% methanol, had no effect on
he NO release evoked by ACh after 180 min (n  2; data
ot shown).
ISCUSSION
he principal findings of this study are that pretreatment
ith metyrapone, an inhibitor of cortisol synthesis, reduced
restress plasma cortisol, blunted the cortisol response to
ental stress, and prevented mental stress-induced endo-
helial dysfunction and impairment of BRS.
ortisol and endothelial function. Endothelial dysfunc-
ion in response to mental stress was first shown by
hiadoni et al. (15) using a similar FMD technique to our
roup and the same mental stress test. In their healthy
olunteers, FMD fell significantly from a mean of 5.0%
2.1%] to 2.8% [2.3%] at the 30-min poststress time point,
hich is approximately the same time point at which we
emeasured FMD. In their study FMD was still impaired
0 min after the stress test but had returned to normal after
40 min. This relatively prolonged time course, which
ontrasts with the rapid return of heart rate and blood
ressure to prestress values, may imply mediation by hu-
oral factors.
More recently, Spieker et al. (16) showed that mental
tress impaired radial artery endothelial function for at least
5 min. In their study, infusion of an endothelin (ET) A
eceptor antagonist prevented endothelial dysfunction.
heir control group showed a reduction in radial artery
MD from 8.0% [1.1%] to 4.1% [1.0%] at the 10-min time
oint. In the group in whom receptor blocker was infused
efore, during, and after the stress test, baseline FMD was
.6% [1.3%] beforehand and nonsignificantly increased at
.4% [1.4%] afterwards.
The findings that suppression of cortisol production with
etyrapone prevented mental stress-induced endothelial
ysfunction are actually consistent with the observation that
T receptor blockade also blocks it (16). Recent evidence
uggests that the hypothalamic-pituitary-adrenal axis and
T system interact closely in their effects on the vasculature
n health and disease. Endothelin-1 is produced by vascular
ndothelial and smooth muscle cells and is a potent vaso-
onstrictor that antagonizes the vasodilator effects of NO
17). Glucocorticoids stimulate the production and release
f ET by vascular smooth muscle cells in cell culture and in snimals and seem to exercise this effect primarily by pro-
oting transcription of prepro-ET mRNA (18,19), which
s probably the major regulatory step in the production of
T (20). In addition, in cultured human endothelial cells,
nhibition of 11-beta-hydroxysteroid dehydrogenase, which
n endothelial cells probably acts to convert cortisol into
nactive cortisone, led to increased levels of ET, but only in
he presence of corticosterone (a cortisol analog) (21). This
as been interpreted as evidence that the activation of the
ascular ET system is dependent on the presence of glu-
ocorticoids. If that is so, then, given the marked reduction
n cortisol levels in our metyrapone group to approximately
0% that of the control group over the 5 h preceding the
ental stress test, our metyrapone group may have been
nable to produce ET-1 in response to mental stress in the
ormal manner owing to lack of the facilitating presence of
ormal levels of glucocorticoids in the preceding hours.
Another emerging strand of evidence links cortisol and
he NO system, the key factor involved in the phenomenon
f FMD. Glucocorticoids are known to inhibit the NO
ynthase (NOS) isoforms iNOS and eNOS (22,23), both
irectly by decreasing their production (24) and indirectly
y reducing production of the essential eNOS cofactor
etrahydrobiopterin (25), thereby impairing “endothelial
unction” in cell and tissue models (26,27).
As the NO and ET systems are functionally antagonistic
n their effects on ET function, and as glucocorticoids have
een shown to inhibit the NO and induce ET, it is hardly
urprising that cortisol impairs endothelial function in
umans. Our data are strong evidence that cortisol mediates
ental stress-induced impairment of endothelial function in
umans.
ortisol and BRS. Reduced BRS is an important inde-
endent predictor of mortality in patients post-myocardial
nfarction, and is particularly associated with sudden cardiac
eath (28). In these circumstances it is likely that reduced
RS both promotes and reflects sympathoexcitation and a
redisposition to ventricular arrhythmias (29). Acute mental
tress also impairs BRS. Thus, it is possible that a reduction
n BRS and an associated reduction in arrhythmia threshold
ay partly explain the link between acute mental stress and
ardiac events, especially SCD. Intuitively, this would apply
o those with previously clinically silent CHD as well as to
hose with known disease, and may be the mechanism
nderlying some cases of SCD in those with no previously
nown heart disease. A direct role for cortisol in mental
tress-induced impairment of BRS has not previously been
escribed in humans. Animal studies support the theory
hat glucocorticoids may act centrally to modify BRS,
ndependent of any effect on blood pressure, and show that
uch actions are of rapid onset, being detectable within
ours (30–32). The administration of cortisol to normal
ubjects, though it raises serum cortisol and produces
ypertension after several days, has not consistently been
hown to reduce BRS (33), and this suggests that in humans
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July 19, 2005:344–50 Stress and Endothelial Dysfunctionny negative influence of cortisol on BRS during the stress
esponse may be acute and somewhat situation specific.
Our finding that suppression of cortisol production with
etyrapone protects against the mental stress-induced im-
airment of BRS, in the absence any significant hemody-
amic effect, supports an acute role for cortisol in this
rocess.
tudy limitations. It is a necessary limitation of our study
hat FMD was not measured immediately before the mental
tress test in order to assess the effect on FMD of metyrap-
ne alone. We chose not to do this in order to keep the
econd visit protocol as close as possible to that of the
aseline visit, and in particular to standardize the length of
ime for which volunteers lay supine, an important issue
hen examining the impact of stress on FMD. We consid-
red the possibility that metyrapone may have a direct
eneficial effect on endothelial function that is independent
f its cortisol-lowering action. In vitro, metyrapone appears
o have generally inhibitory, but in some cases stimulatory,
ffects on some P-450 enzymes. For example, it was shown
o have direct inhibitory effect on endothelium derived
yperpolarizing factor-mediated vasorelaxation via its in-
ibitory action on the cytochrome P-450 enzyme system
34). Because eNOS is a P-450 enzyme, we were concerned
o exclude a direct stimulatory effect of metyrapone on NO
roduction via direct effects on eNOS gene expression or
nzyme activity. Our in vitro studies in HUVECs make this
ery unlikely because metyrapone had no evident effect on
he basal release of NO (data not shown) or, more impor-
antly, on acetylcholine-stimulated NO release.
The long interval between tests introduces an element of
iurnal variation but was dictated by the pharmacodynamics
f metyrapone and could not be avoided. Diurnal variation
n FMD/endothelial function has been described previously
35,36), with lower values in the morning than the evening,
n both a group with variant angina and in a control group.
his pattern mirrors the normal diurnal variation in cortisol
evels, which, in view of our results, may suggest an effect of
ordinary” stress/cortisol levels on FMD even without
dded laboratory mental stress. However, even if underlying
MD had improved over the course of the day, it was still
arkedly reduced following stress in the placebo group
ompared with the morning baseline, but not in the me-
yrapone group.
In addition to its inhibitory effect on 11-beta-
ydroxylase, metyrapone also inhibits the enzyme 11-beta-
SD type I, which catalyzes the peripheral conversion of
nactive cortisone to active cortisol. Accordingly, it is
ossible that the impact of metyrapone on tissue cortisol
evels may have been greater than that on plasma cortisol
evels. However, this does not weaken our conclusion that
ortisol plays a role in the endothelial dysfunction induced
y mental stress.
Sympathetic activation has previously been shown to
mpair brachial artery FMD (37). Although our data suggest
hat cortisol plays an important role in the FMD response totress, we cannot exclude an additional effect of sympathetic
ctivation. Indeed, our observations of a blunting of the
ental stress-induced impairment of BRS by metyrapone
uggest that there is also an interaction between cortisol and
aroreflex function.
Finally, we did not measure brachial artery flow. We
annot exclude an increase in the reactive hyperemia flow
timulus in the metyrapone group versus placebo group, but
his is highly unlikely. Even if this were so, the most likely
xplanation would be greater microvascular NO activity.
ummary. We present data that suggest that cortisol may
ediate mental stress-induced endothelial dysfunction and
mpairment of BRS. A deleterious direct effect of cortisol on
ndothelial function and BRS may contribute to the link
etween mental stress and acute cardiac events.
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